The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy

Oncologist. 2022 Jul 5;27(7):e604-e605. doi: 10.1093/oncolo/oyac087.

Abstract

The article by Wilson et al., published in the February 2021 issue, reported the prognostic value of circulating tumor DNA (ctDNA) sequencing in head and neck squamous cell carcinoma (HNSCC), noting TP53 as the most altered and concordant gene in ctDNA and tDNA. This Letter to the Editor further considers the role of TP53 alteration in the prognosis prediction of immunotherapy in HNSCC.

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Squamous Cell* / genetics
  • Carcinoma, Squamous Cell* / pathology
  • Carcinoma, Squamous Cell* / therapy
  • Head and Neck Neoplasms* / genetics
  • Head and Neck Neoplasms* / therapy
  • Humans
  • Immunotherapy
  • Prognosis
  • Squamous Cell Carcinoma of Head and Neck / therapy
  • Tumor Suppressor Protein p53 / genetics

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53